Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Levomilnacipran | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | Levomilnacipran | hsa00270 | Cysteine and methionine metabolism | 1.92E-02 | 2 | Q96RQ9, P40926 | IL4I1, MDH2 | More | | Levomilnacipran | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 2.87E-03 | 3 | P06865, O15466, Q9H4F1 | HEXA, ST8SIA5, ST6GALNAC4 | More | | Levomilnacipran | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | | Levomilnacipran | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 2.18E-02 | 2 | P49841, Q9NRA1 | GSK3B, PDGFC | More | | Levomilnacipran | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | Levomilnacipran | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Levomilnacipran | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | | Levomilnacipran | hsa04010 | MAPK signaling pathway | 4.76E-02 | 5 | Q15283, P21860, Q12933, P01584, O14944 | RASA2, ERBB3, TRAF2, IL1B, EREG | More | | Levomilnacipran | hsa04020 | Calcium signaling pathway | 3.61E-02 | 4 | Q96DU7, Q08828, Q13557, P21860 | ITPKC, ADCY1, CAMK2D, ERBB3 | More | | Levomilnacipran | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Levomilnacipran | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | Levomilnacipran | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Levomilnacipran | hsa04610 | Complement and coagulation cascades | 2.78E-03 | 1 | P0C0L4 | C4A | More | | Levomilnacipran | hsa04613 | Neutrophil extracellular trap formation | 4.20E-02 | 5 | P04908, Q93077, P68431, O43315, Q16539 | H2AC4; H2AC8, HIST1H2AC, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | | Levomilnacipran | hsa04650 | Natural killer cell mediated cytotoxicity | 2.94E-02 | 3 | P16298, P50591, Q02750 | PPP3CB, TNFSF10, MAP2K1 | More | | Levomilnacipran | hsa04668 | TNF signaling pathway | 1.26E-02 | 4 | Q12933, Q99941, P01584, O95429 | TRAF2, CREBL1, IL1B, BAG4 | More | | Levomilnacipran | hsa04713 | Circadian entrainment | 4.25E-02 | 3 | Q13557, Q02153, Q08828 | CAMK2D, GUCY1B3, ADCY1 | More | | Levomilnacipran | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Levomilnacipran | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | Levomilnacipran | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.25E-02 | 3 | P01584, Q08828, Q13557 | IL1B, ADCY1, CAMK2D | More | | Levomilnacipran | hsa04911 | Insulin secretion | 2.23E-02 | 3 | Q08828, Q99941, Q13557 | ADCY1, CREBL1, CAMK2D | More | | Levomilnacipran | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | | Levomilnacipran | hsa04916 | Melanogenesis | 2.18E-02 | 2 | P49841, Q01726 | GSK3B, MC1R | More | | Levomilnacipran | hsa04932 | Non-alcoholic fatty liver disease | 3.35E-03 | 7 | P49841, Q12933, P01584, P12074, O15239, Q16718, O14521 | GSK3B, TRAF2, IL1B, COX6A1, NDUFA1, NDUFA5, SDHD | More | | Levomilnacipran | hsa04934 | Cushing syndrome | 6.07E-03 | 4 | Q99941, Q08828, O15169, Q13557 | CREBL1, ADCY1, AXIN1, CAMK2D | More | | Levomilnacipran | hsa04966 | Collecting duct acid secretion | 1.68E-02 | 2 | P02730, P00918 | SLC4A1, CA2 | More | | Levomilnacipran | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | Levomilnacipran | hsa05010 | Alzheimer disease | 1.23E-02 | 8 | Q92542, O15239, P05496, P12074, P01584, Q12933, O15169, P43686 | NCSTN, NDUFA1, ATP5G1, COX6A1, IL1B, TRAF2, AXIN1, PSMC4 | More | | Levomilnacipran | hsa05012 | Parkinson disease | 3.53E-02 | 6 | P62987, O15239, P12074, P05496, P43686, Q13557 | UBA52, NDUFA1, COX6A1, ATP5G1, PSMC4, CAMK2D | More | | Levomilnacipran | hsa05014 | Amyotrophic lateral sclerosis | 2.99E-02 | 7 | O15239, P12074, P05496, Q12933, P43686, P37198, P35658 | NDUFA1, COX6A1, ATP5G1, TRAF2, PSMC4, NUP62, NUP214 | More | | Levomilnacipran | hsa05020 | Prion disease | 1.94E-03 | 11 | P01584, P46531, O15239, Q16718, O14521, P05496, P12074, P43686, P49841, Q99941, Q16539 | IL1B, NOTCH1, NDUFA1, NDUFA5, SDHD, ATP5G1, COX6A1, PSMC4, GSK3B, CREBL1, MAPK14 | More | | Levomilnacipran | hsa05022 | Pathways of neurodegeneration - multiple diseases | 2.29E-04 | 15 | P49841, O15239, Q16718, O14521, P12074, P05496, Q12933, Q13561, Q16539, O15169, P01584, Q08752, Q13557, P62987, P43686 | GSK3B, NDUFA1, NDUFA5, SDHD, COX6A1, ATP5G1, TRAF2, DCTN2, MAPK14, AXIN1, IL1B, PPID, CAMK2D, UBA52, PSMC4 | More | | Levomilnacipran | hsa05133 | Pertussis | 4.94E-02 | 1 | P0C0L4 | C4A | More | | Levomilnacipran | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | | Levomilnacipran | hsa05170 | Human immunodeficiency virus 1 infection | 6.02E-03 | 5 | Q02750, P62879, P16298, Q05397, P20333 | MAP2K1, GNB2, PPP3CB, PTK2, TNFRSF1B | More | | Levomilnacipran | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | Levomilnacipran | hsa05218 | Melanoma | 1.07E-02 | 3 | P09619, Q9GZP0, Q02750 | PDGFRB, PDGFD, MAP2K1 | More | | Levomilnacipran | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | | Levomilnacipran | hsa05231 | Choline metabolism in cancer | 9.39E-03 | 4 | Q02750, P09619, Q9GZP0, O15245 | MAP2K1, PDGFRB, PDGFD, SLC22A1 | More | | Levomilnacipran | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 3.10E-02 | 3 | Q8IZS8, P54284, P13612 | CACNA2D3, CACNB3, ITGA4 | More | | Levomilnacipran | hsa05414 | Dilated cardiomyopathy | 2.11E-02 | 4 | Q8IZS8, P54284, P13612, P26678 | CACNA2D3, CACNB3, ITGA4, PLN | More | | Levomilnacipran | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | Milnacipran | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | Milnacipran | hsa00270 | Cysteine and methionine metabolism | 1.92E-02 | 2 | Q96RQ9, P40926 | IL4I1, MDH2 | More | | Milnacipran | hsa00310 | Lysine degradation | 1.53E-02 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | Milnacipran | hsa00562 | Inositol phosphate metabolism | 2.54E-03 | 4 | P27987, Q13572, Q96PE3, P42338 | ITPKB, ITPK1, INPP4A, PIK3CB | More | | Milnacipran | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 2.87E-03 | 3 | P06865, O15466, Q9H4F1 | HEXA, ST8SIA5, ST6GALNAC4 | More | | Milnacipran | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | | Milnacipran | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 2.18E-02 | 2 | P49841, Q9NRA1 | GSK3B, PDGFC | More | | Milnacipran | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | Milnacipran | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Milnacipran | hsa03040 | Spliceosome | 3.94E-04 | 8 | Q14562, O43143, O60508, P08579, P26368, Q13595, Q01130, O43447 | DHX8, DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS2, PPIH | More | | Milnacipran | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | | Milnacipran | hsa04010 | MAPK signaling pathway | 4.76E-02 | 5 | Q15283, P21860, Q12933, P01584, O14944 | RASA2, ERBB3, TRAF2, IL1B, EREG | More | | Milnacipran | hsa04014 | Ras signaling pathway | 3.62E-02 | 5 | P42338, P49767, P0DP23, P63218, P50151 | PIK3CB, VEGFC, CALM1, GNG5, GNG10 | More | | Milnacipran | hsa04020 | Calcium signaling pathway | 9.43E-06 | 12 | P27987, Q96DU7, Q08828, P21796, Q16566, Q13557, P21860, P30679, O15399, P0DP23, P23634, P49767 | ITPKB, ITPKC, ADCY1, VDAC1, CAMK4, CAMK2D, ERBB3, GNA15, GRIN2D, CALM1, ATP2B4, VEGFC | More | | Milnacipran | hsa04024 | cAMP signaling pathway | 1.49E-02 | 5 | P42338, P0DP23, P23634, Q16566, O15399 | PIK3CB, CALM1, ATP2B4, CAMK4, GRIN2D | More | | Milnacipran | hsa04070 | Phosphatidylinositol signaling system | 1.49E-03 | 5 | P0DP23, P42338, Q96PE3, Q13572, P27987 | CALM1, PIK3CB, INPP4A, ITPK1, ITPKB | More | | Milnacipran | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Milnacipran | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | Milnacipran | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Milnacipran | hsa04371 | Apelin signaling pathway | 7.45E-03 | 5 | P63218, P50151, Q13485, Q16566, P0DP23 | GNG5, GNG10, SMAD4, CAMK4, CALM1 | More | | Milnacipran | hsa04610 | Complement and coagulation cascades | 2.78E-03 | 1 | P0C0L4 | C4A | More | | Milnacipran | hsa04613 | Neutrophil extracellular trap formation | 4.20E-02 | 5 | P04908, Q93077, P68431, O43315, Q16539 | H2AC4; H2AC8, HIST1H2AC, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | | Milnacipran | hsa04650 | Natural killer cell mediated cytotoxicity | 2.94E-02 | 3 | P16298, P50591, Q02750 | PPP3CB, TNFSF10, MAP2K1 | More | | Milnacipran | hsa04664 | Fc epsilon RI signaling pathway | 2.32E-02 | 3 | P42338, P07948, P09917 | PIK3CB, LYN, ALOX5 | More | | Milnacipran | hsa04666 | Fc gamma R-mediated phagocytosis | 4.10E-02 | 3 | P07948, P42338, P23528 | LYN, PIK3CB, CFL1 | More | | Milnacipran | hsa04668 | TNF signaling pathway | 1.26E-02 | 4 | Q12933, Q99941, P01584, O95429 | TRAF2, CREBL1, IL1B, BAG4 | More | | Milnacipran | hsa04713 | Circadian entrainment | 9.05E-04 | 7 | O15399, P0DP23, Q13557, Q02153, P63218, P50151, Q08828 | GRIN2D, CALM1, CAMK2D, GUCY1B3, GNG5, GNG10, ADCY1 | More | | Milnacipran | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Milnacipran | hsa04720 | Long-term potentiation | 6.32E-04 | 6 | Q16566, P16298, P0DP23, P51812, O15399, Q02750 | CAMK4, PPP3CB, CALM1, RPS6KA3, GRIN2D, MAP2K1 | More | | Milnacipran | hsa04724 | Glutamatergic synapse | 4.10E-02 | 3 | O15399, P63218, P50151 | GRIN2D, GNG5, GNG10 | More | | Milnacipran | hsa04725 | Cholinergic synapse | 5.94E-03 | 4 | P63218, P50151, Q16566, P42338 | GNG5, GNG10, CAMK4, PIK3CB | More | | Milnacipran | hsa04726 | Serotonergic synapse | 1.52E-02 | 4 | P63218, P50151, P33260, P09917 | GNG5, GNG10, CYP2C18, ALOX5 | More | | Milnacipran | hsa04728 | Dopaminergic synapse | 4.47E-02 | 4 | P63218, P50151, P0DP23, O00327 | GNG5, GNG10, CALM1, ARNTL | More | | Milnacipran | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.25E-02 | 3 | P01584, Q08828, Q13557 | IL1B, ADCY1, CAMK2D | More | | Milnacipran | hsa04911 | Insulin secretion | 2.23E-02 | 3 | Q08828, Q99941, Q13557 | ADCY1, CREBL1, CAMK2D | More | | Milnacipran | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | | Milnacipran | hsa04916 | Melanogenesis | 2.18E-02 | 2 | P49841, Q01726 | GSK3B, MC1R | More | | Milnacipran | hsa04925 | Aldosterone synthesis and secretion | 3.14E-02 | 3 | P0DP23, Q16566, P23634 | CALM1, CAMK4, ATP2B4 | More | | Milnacipran | hsa04926 | Relaxin signaling pathway | 5.70E-03 | 5 | P42338, P63218, P50151, P49767, P30679 | PIK3CB, GNG5, GNG10, VEGFC, GNA15 | More | | Milnacipran | hsa04932 | Non-alcoholic fatty liver disease | 3.35E-03 | 7 | P49841, Q12933, P01584, P12074, O15239, Q16718, O14521 | GSK3B, TRAF2, IL1B, COX6A1, NDUFA1, NDUFA5, SDHD | More | | Milnacipran | hsa04934 | Cushing syndrome | 6.07E-03 | 4 | Q99941, Q08828, O15169, Q13557 | CREBL1, ADCY1, AXIN1, CAMK2D | More | | Milnacipran | hsa04966 | Collecting duct acid secretion | 1.68E-02 | 2 | P02730, P00918 | SLC4A1, CA2 | More | | Milnacipran | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | Milnacipran | hsa05010 | Alzheimer disease | 1.23E-02 | 8 | Q92542, O15239, P05496, P12074, P01584, Q12933, O15169, P43686 | NCSTN, NDUFA1, ATP5G1, COX6A1, IL1B, TRAF2, AXIN1, PSMC4 | More | | Milnacipran | hsa05012 | Parkinson disease | 3.53E-02 | 6 | P62987, O15239, P12074, P05496, P43686, Q13557 | UBA52, NDUFA1, COX6A1, ATP5G1, PSMC4, CAMK2D | More | | Milnacipran | hsa05014 | Amyotrophic lateral sclerosis | 2.99E-02 | 7 | O15239, P12074, P05496, Q12933, P43686, P37198, P35658 | NDUFA1, COX6A1, ATP5G1, TRAF2, PSMC4, NUP62, NUP214 | More | | Milnacipran | hsa05017 | Spinocerebellar ataxia | 5.94E-03 | 4 | Q8TB72, O15399, P42338, P21796 | PUM2, GRIN2D, PIK3CB, VDAC1 | More | | Milnacipran | hsa05020 | Prion disease | 1.94E-03 | 11 | P01584, P46531, O15239, Q16718, O14521, P05496, P12074, P43686, P49841, Q99941, Q16539 | IL1B, NOTCH1, NDUFA1, NDUFA5, SDHD, ATP5G1, COX6A1, PSMC4, GSK3B, CREBL1, MAPK14 | More | | Milnacipran | hsa05022 | Pathways of neurodegeneration - multiple diseases | 2.29E-04 | 15 | P49841, O15239, Q16718, O14521, P12074, P05496, Q12933, Q13561, Q16539, O15169, P01584, Q08752, Q13557, P62987, P43686 | GSK3B, NDUFA1, NDUFA5, SDHD, COX6A1, ATP5G1, TRAF2, DCTN2, MAPK14, AXIN1, IL1B, PPID, CAMK2D, UBA52, PSMC4 | More | | Milnacipran | hsa05034 | Alcoholism | 3.62E-02 | 5 | O15399, Q16566, P0DP23, P63218, P50151 | GRIN2D, CAMK4, CALM1, GNG5, GNG10 | More | | Milnacipran | hsa05133 | Pertussis | 4.94E-02 | 1 | P0C0L4 | C4A | More | | Milnacipran | hsa05163 | Human cytomegalovirus infection | 4.19E-02 | 5 | P42338, P63218, P50151, P0DP23, P30101 | PIK3CB, GNG5, GNG10, CALM1, PDIA3 | More | | Milnacipran | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 2.44E-03 | 9 | P42338, P62879, P63218, P50151, P16298, Q02750, P07948, P0DP23, P0CG47 | PIK3CB, GNB2, GNG5, GNG10, PPP3CB, MAP2K1, LYN, CALM1, UBB | More | | Milnacipran | hsa05170 | Human immunodeficiency virus 1 infection | 7.38E-04 | 11 | P42338, Q02750, P62879, P63218, P50151, P16298, P0DP23, Q05397, P30101, P23528, P20333 | PIK3CB, MAP2K1, GNB2, GNG5, GNG10, PPP3CB, CALM1, PTK2, PDIA3, CFL1, TNFRSF1B | More | | Milnacipran | hsa05204 | Chemical carcinogenesis | 4.62E-02 | 2 | P78417, P33260 | GSTO1, CYP2C18 | More | | Milnacipran | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | Milnacipran | hsa05214 | Glioma | 2.32E-02 | 3 | P0DP23, Q16566, P42338 | CALM1, CAMK4, PIK3CB | More | | Milnacipran | hsa05218 | Melanoma | 1.07E-02 | 3 | P09619, Q9GZP0, Q02750 | PDGFRB, PDGFD, MAP2K1 | More | | Milnacipran | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | | Milnacipran | hsa05231 | Choline metabolism in cancer | 9.39E-03 | 4 | Q02750, P09619, Q9GZP0, O15245 | MAP2K1, PDGFRB, PDGFD, SLC22A1 | More | | Milnacipran | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 3.10E-02 | 3 | Q8IZS8, P54284, P13612 | CACNA2D3, CACNB3, ITGA4 | More | | Milnacipran | hsa05414 | Dilated cardiomyopathy | 2.11E-02 | 4 | Q8IZS8, P54284, P13612, P26678 | CACNA2D3, CACNB3, ITGA4, PLN | More | | Milnacipran | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | |